Covered recipient · General Payments record
KRIS V KOWDLEY
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$331,375.16
180 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $162,606.25 | 41 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,666.38 | 35 |
| Travel and Lodging | $24,753.12 | 51 |
| Honoraria | $4,980.00 | 1 |
| Food and Beverage | $3,369.41 | 52 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $65,993.52 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $43,105.68 | 34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40,786.89 | 21 |
| Novo Nordisk Inc | $40,570.27 | 16 |
| Ipsen Biopharmaceuticals, Inc | $33,368.83 | 10 |
| Gilead Sciences, Inc. | $28,352.21 | 22 |
| Mirum Pharmaceuticals, Inc. | $19,749.12 | 10 |
| Boehringer Ingelheim International GmbH | $15,932.50 | 3 |
| GlaxoSmithKline, LLC. | $14,400.00 | 3 |
| Intercept Pharmaceuticals, Inc. | $12,568.30 | 6 |
| CSL Behring | $8,357.82 | 7 |
| Merck Sharp & Dohme LLC | $3,965.00 | 2 |
| Kowa Research Institute, Inc. | $3,410.72 | 3 |
| Corcept Therapeutics | $729.84 | 2 |
| Ipsen Innovation | $54.53 | 1 |
| ORPHALAN INC | $29.93 | 1 |
Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KRIS V KOWDLEY
NPI 1699850404 · CMS profile ID 31072
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
SEATTLE, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1699850404?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KRIS V KOWDLEY, NPI 1699850404, CMS profile ID 31072. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699850404?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KRIS V KOWDLEY, NPI 1699850404, CMS profile ID 31072. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699850404?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KRIS V KOWDLEY, NPI 1699850404, CMS profile ID 31072, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1699850404?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
180 matching records · $331,375.16 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–180 of 180.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| CSL Behring | $2,250.00 | 02/06/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232359947 | CMS |
| Gilead Sciences, Inc. | $5,000.00 | 02/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234350932 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,675.00 | 02/03/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223049648 | CMS |
| CSL Behring | $1,250.00 | 01/31/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232359945 | CMS |
| GlaxoSmithKline, LLC. | $6,000.00 | 01/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191030085 | CMS |
| GlaxoSmithKline, LLC. | $3,600.00 | 01/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191531169 | CMS |
| Madrigal Pharmaceuticals | $17.51 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279136 | CMS |
| Gilead Sciences, Inc. | $14.92 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234572520 | CMS |
| Corcept Therapeutics | $600.00 | 01/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214205989 | CMS |
| Boehringer Ingelheim International GmbH | $6,247.50 | 01/15/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215874223 | CMS |
| GlaxoSmithKline, LLC. | $4,800.00 | 01/15/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190741078 | CMS |
| Intercept Pharmaceuticals, Inc. | $6.59 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249873632 | CMS |
| Gilead Sciences, Inc. | $48.00 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234414658 | CMS |
| Kowa Research Institute, Inc. | $1,950.00 | 01/10/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184285927 | CMS |
| Madrigal Pharmaceuticals | $19.39 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279134 | CMS |
| Madrigal Pharmaceuticals | $108.55 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279124 | CMS |
| Madrigal Pharmaceuticals | $5,600.00 | 01/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279126 | CMS |
| Madrigal Pharmaceuticals | $376.60 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279128 | CMS |
| Madrigal Pharmaceuticals | $282.05 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279130 | CMS |
| Madrigal Pharmaceuticals | $2,000.00 | 01/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279132 | CMS |
| Novo Nordisk Inc | $4,317.50 | 01/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188900939 | CMS |
| Mirum Pharmaceuticals, Inc. | $2,175.00 | 01/06/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241158827 | CMS |
| Mirum Pharmaceuticals, Inc. | $85.80 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241158831 | CMS |
| Mirum Pharmaceuticals, Inc. | $115.86 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241158834 | CMS |
| Mirum Pharmaceuticals, Inc. | $115.86 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241158838 | CMS |
| Mirum Pharmaceuticals, Inc. | $2,175.00 | 01/06/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241158842 | CMS |
| Mirum Pharmaceuticals, Inc. | $85.80 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241158846 | CMS |
| Madrigal Pharmaceuticals | $5,600.00 | 01/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279120 | CMS |
| Madrigal Pharmaceuticals | $570.00 | 01/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248279122 | CMS |
| Novo Nordisk Inc | $1,570.00 | 01/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189163034 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,022,640.18 | 381 |
| PY2024 | Recipient | $4,500.00 | 1 |
| PY2024 | Principal investigator | $657,039.17 | 113 |
| PY2023 | Principal investigator | $285,269.04 | 87 |
| PY2022 | Principal investigator | $252,639.53 | 79 |
| PY2021 | Principal investigator | $671,165.42 | 195 |
| PY2020 | Principal investigator | $487,137.14 | 162 |
| PY2019 | Principal investigator | $1,131,691.37 | 197 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
381 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 12/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,913.44 | 12/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,823.09 | 12/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729795 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547179 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $955.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547181 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547183 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $765.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 12/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.00 | 12/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 12/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 12/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729799 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $987.30 | 12/15/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800724 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,495.00 | 12/15/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,250.00 | 12/11/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729569 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $174.80 | 12/11/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547175 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,190.70 | 12/11/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547177 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,998.00 | 12/11/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307485 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,253.81 | 12/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254040 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,750.00 | 12/10/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $715.00 | 12/10/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729791 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,507.62 | 12/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $910.00 | 12/03/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $640.00 | 12/03/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729565 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,600.00 | 12/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207563 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 12/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729471 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 12/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,930.12 | 11/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,896.17 | 11/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 11/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 11/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 11/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 11/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729785 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,253.81 | 11/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,915.32 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $83.40 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $97.30 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $250.00 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $152.90 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $250.20 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.35 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.50 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.35 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $250.00 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.35 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $152.90 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $604.65 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,056.40 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.10 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.65 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $278.00 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,001.50 | 11/21/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729561 |
| Principal investigator 1 | Gilead Sciences, Inc. | $867.00 | 11/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 11/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $250.00 | 11/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $750.00 | 11/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729773 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 11/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800718 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 11/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800720 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 11/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800722 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,000.00 | 11/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210403 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,000.00 | 11/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210412 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,949.40 | 11/14/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 11/13/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $465.00 | 11/13/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729775 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,729.20 | 11/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800714 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 11/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800716 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,000.00 | 11/07/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547169 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 11/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808250 |
| Principal investigator 1 | GENZYME CORPORATION | $16,537.00 | 11/04/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A randomized, double-blind, Phase 3, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active iGG4-related disease. | No dispute reported | 06/30/2026 | 1226130716 |
| Principal investigator 1 | Gilead Sciences, Inc. | $13,962.30 | 11/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729459 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 11/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729515 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 10/29/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,250.41 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,913.44 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 10/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729765 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,974.93 | 10/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229205654 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,381.40 | 10/23/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547165 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,542.00 | 10/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207554 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $377.00 | 10/16/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547163 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,166.63 | 10/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,785.00 | 10/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 10/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 10/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,000.00 | 10/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,655.00 | 10/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 10/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729749 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,323.35 | 10/09/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547159 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,036.80 | 10/09/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547161 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,253.81 | 10/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251465 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,347.45 | 10/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210421 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 10/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,047.00 | 10/03/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800712 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,323.35 | 10/03/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547157 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,912.82 | 10/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251241 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,101.42 | 10/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251244 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $566.07 | 10/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250860 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $690.52 | 10/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729443 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729447 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 10/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/29/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,618.76 | 09/29/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.02 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729701 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,448.59 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,448.59 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,377.74 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,913.44 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,333.13 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 09/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729739 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,640.00 | 09/26/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $819.18 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,715.50 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $378.30 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.00 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $599.40 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,299.50 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.00 | 09/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729699 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,600.00 | 09/23/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800704 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,448.70 | 09/22/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800702 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 09/18/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547147 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,500.00 | 09/18/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547149 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 09/18/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547151 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $48.00 | 09/18/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547153 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,323.00 | 09/18/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,361.90 | 09/15/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729509 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,912.82 | 09/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250018 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,000.00 | 09/04/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729507 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,912.82 | 09/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249707 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,100.55 | 09/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729399 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729411 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729435 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 09/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21,632.57 | 08/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $37,106.05 | 08/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $104.94 | 08/26/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729495 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,000.00 | 08/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207545 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,825.64 | 08/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249252 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,190.70 | 08/07/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547139 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,000.00 | 08/07/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547141 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,000.00 | 08/07/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547143 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $10,000.00 | 08/07/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547145 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,439.00 | 08/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729401 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729403 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729407 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729433 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 08/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545929 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,112.75 | 07/31/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,604.97 | 07/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,975.14 | 07/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729683 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,912.82 | 07/30/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 07/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $339.66 | 07/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 07/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 07/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729691 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 07/22/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808248 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,447.00 | 07/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207537 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,611.70 | 07/21/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800698 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $24,496.70 | 07/17/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547137 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,388.95 | 07/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229205648 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 07/14/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808246 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,420.44 | 07/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246997 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,073.37 | 07/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248247001 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000.00 | 07/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800694 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,735.00 | 07/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729431 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 07/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,109.34 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.02 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,913.44 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,035.87 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,010.02 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729647 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,913.44 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729649 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,380.07 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,324.79 | 06/30/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729661 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $72.28 | 06/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $278.00 | 06/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $201.55 | 06/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $173.75 | 06/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729655 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.10 | 06/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 06/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 06/24/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729679 |
| Principal investigator 1 | Ipsen Pharma SAS | $700.00 | 06/24/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307483 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,822.85 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245462 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,253.81 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245467 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,473.30 | 06/11/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $72.28 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,922.00 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,077.25 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $375.30 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,922.00 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $278.00 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729633 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $201.55 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $173.75 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $742.26 | 06/06/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729657 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,075.52 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245019 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,420.44 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245023 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,253.81 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245027 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,659.89 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245031 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,000.00 | 06/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729383 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729385 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729387 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729389 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729393 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 05/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 05/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729665 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.02 | 05/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729667 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $304.42 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729489 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,980.00 | 05/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800690 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,190.70 | 05/22/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547119 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,542.00 | 05/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207522 |
| Principal investigator 1 | Gilead Sciences, Inc. | $19,693.80 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229210379 |
| Principal investigator 1 | Gilead Sciences, Inc. | $200.00 | 05/13/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207515 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,381.40 | 05/08/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547117 |
| Principal investigator 1 | Gilead Sciences, Inc. | $10,684.51 | 05/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229205637 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,810.66 | 05/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248243170 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,800.00 | 05/02/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729371 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729373 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729375 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729377 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729379 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729381 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 05/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,010.02 | 04/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 04/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,324.79 | 04/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 04/28/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729397 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729671 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 04/23/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729675 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,100.45 | 04/23/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547115 |
| Principal investigator 1 | Gilead Sciences, Inc. | $17,323.00 | 04/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,495.00 | 04/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,495.00 | 04/17/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,410.00 | 04/16/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729599 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $87.75 | 04/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161490 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 04/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161494 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $108.00 | 04/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161847 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $289.00 | 04/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729357 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729359 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729361 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729363 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729365 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729369 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $200.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.00 | 04/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729603 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 04/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547111 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 04/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547113 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $400.00 | 03/31/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161830 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $400.00 | 03/31/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161839 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 03/31/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,109.34 | 03/27/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729581 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,366.47 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185554166 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,622.36 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | LINERIXIBAT (GSK2330672) ILEAL BILE ACID TRANSPORT (IBAT) INHIBITOR (O | No dispute reported | 06/30/2026 | 1192161834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 03/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 03/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.00 | 03/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729593 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,197.00 | 03/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800688 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,822.85 | 03/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241153 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $50,813.40 | 03/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1185554168 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,200.00 | 03/12/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800686 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $10,982.70 | 03/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240179 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,100.45 | 03/04/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729333 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729335 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729337 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729339 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729341 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729343 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 03/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729347 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $353.76 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729351 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220729481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,022.00 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 02/25/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729587 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 02/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192161499 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,291.15 | 02/18/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 02/13/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,500.00 | 02/13/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 02/13/2025 | Non-covered Recipient Entity Liver Institute Northwest | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220729579 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $968.40 | 02/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800684 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $10,739.34 | 02/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239476 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $29,748.75 | 02/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729321 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729323 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729327 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729329 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729331 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 02/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545921 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,388.95 | 01/29/2025 | Non-covered Recipient Entity LIVER INSTITUTE NORTHWEST PLLC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204829 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,845.79 | 01/29/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547105 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,622.36 | 01/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | LINERIXIBAT (GSK2330672) ILEAL BILE ACID TRANSPORT (IBAT) INHIBITOR (O | No dispute reported | 06/30/2026 | 1192161501 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,701.90 | 01/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800682 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,190.70 | 01/21/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547103 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,732.00 | 01/21/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307479 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,492.50 | 01/17/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800680 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,367.14 | 01/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729319 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220729353 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 01/01/2025 | Non-covered Recipient Entity Liver Institute Northwest | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545919 |